OncLive TV

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

Michael Wang, MD, discusses the utility of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

Luis E. Raez, MD, discusses how the COVID-19 pandemic has impacted the treatment of patients with lung cancer.

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Kevin Hughes, MD, discusses mutational risk in oncology.

Christopher A. Yasenchak, MD, discusses the safety profile of brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

John M. Burke, MD, discusses research with tafasitamab (MOR208) in lymphoma.

Melissa K. Accordino, MD, MS, discusses the utility of liquid biopsies in breast cancer.

Marc J. Braunstein, MD, PhD, discusses quadruplet therapies in multiple myeloma.

Thomas Herzog, MD, discusses the data that led to the FDA approval of the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab and whose cancer is associated with homologous recombination deficiency–positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.

Erika P. Hamilton, MD, discusses the evolution of treatment in HER2-positive breast cancer.

Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

Udai Banerji, MD, discusses the results from a phase 1 trial with the combination of VS-6766 (CH5126766) and defactinib in KRAS-mutant tumors.

Manish A. Shah, MD, discusses biomarkers of response to immunotherapy gastric/gastroesophageal cancer.

Andre Goy, MD, MS, compares the toxicity profiles of available BTK inhibitors in mantle cell lymphoma.

Michael Wang, MD, discusses the results of the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Eric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.